PARPis have been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of several cancers with BRCA1/BRCA2 mutations, or other deficiencies in HR components. The gene discussed is BRCA2; the disease is cancer.